4 reports

  • PARTNERSHIPS
  • VENTURE FINANCING

Among the ## evaluable patients, one patient underwent partial response (PR) after the CX-## treatment and stayed in the trial for one year.

  • Cancer
  • Pharmaceutical
  • Taiwan
  • Company
  • Senhwa Biosciences, Inc.
  • PHARMAENGINE INC, PHARMACEUTICALS & HEALTHCARE, DEAL DETAILS
  • LICENSING AGREEMENTS

Cash (US$ m) Deal Rationale Deal Information Deal Status Completed Date Deal Financials Deal Value (US$ m) Upfront Payment (US$ m) Milestone Payment (US$ m) Deal Product NBTXR-##_ Completed ##-Aug-2012 Product Description ## ## ## ## Companies Information Licensor Company Information

  • Cancer
  • Pathology
  • Taiwan
  • Deals & Alliance
  • PharmaEngine, Inc.
  • MEDIGENE ENTERS INTO LICENSING AGREEMENT WITH SYNCORE BIOTECHNOLOGY FOR ENDOTAG-1

EndoTAG-##, a novel composition of cytostatic drug paclitaxel combined with neutral and positive lipids used for the treatment of triple-negative breast cancer (TNBC) and pancreatic cancer.

  • Cancer
  • Healthcare
  • Pharmaceutical
  • Taiwan
  • Sinphar Pharmaceutical Co., Ltd.
  • PHARMAESSENTIA RAISES USD20.5 MILLION IN RIGHTS OFFERING OF SHARES
  • PHARMAESSENTIA RAISES USD88 MILLION IN PUBLIC OFFERING OF SHARES

The company also develops oncology drug for various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer and breast cancer.

  • Cancer
  • Taiwan
  • Corporate Finance
  • Deals & Alliance
  • PharmaEssentia Corporation